Cost-Effectiveness Analysis of Budesonide/Formoterol and Fluticasone/Salmeterol for Stable Chronic Obstructive Lung Disease
DOI:
https://doi.org/10.36497/jri.v42i4.378Keywords:
COPD, FEV1/FVC ratio, inhaled corticosteroid, Long-acting Beta-2 AgonistAbstract
Background: Chronic Obstructive Pulmonary Disease (COPD) is one of the four largest types of non-communicable diseases in the world, requiring long-term and routine treatment. Treatment with the inhalation route is in the form of a dry-powder inhaler (DPI) which is easy to use and carry. Combination of corticosteroid and long-acting beta-2 agonist (LABA) in the form of DPI available in Indonesia are budesonide/formoterol and salmeterol/fluticasone. The purpose was to identify therapy was more cost-effective between budesonide/formoterol than fluticasone/salmeterol in clinical symptoms using COPD assessment test (CAT) value and lung function in FEV1/FVC (Forced Expiratory Volume in First Seconds/Forced Vital Capacity) ratio.
Methods: This research study was pre-post design with cost-effectiveness analysis, in outpatient COPD patients in a hospital in Gresik Regency, from October 2019 to January 2020. There were two outcomes of respondents in this study, namely lung function seen from the value of FEV1, and clinical symptoms seen from the value of CAT. The study used hospital perspective.
Results: There were 38 respondents involved. Fluticasone/salmeterol therapy was more effective than the budesonide/formoterol group in improving FEV1/FVC ratio, while budesonide/formoterol was more effective than the fluticasone/salmeterol group in improving clinical symptoms by CAT assessment. The average cost effectiveness ratio (ACER) value of lung function between the fluticasone/salmeterol group (IDR.176.465/Liter) was lower than that of budesonide/formoterol (IDR.296.832/Liter). The ACER clinical symptoms value between the fluticasone/salmeterol group (IDR.16,283/score) was smaller than that of budesonide/formoterol (IDR.17,340/score).
Conclusion: Fluticasone/salmeterol was more cost-effective than budesonide/formoterol in improving lung function. Meanwhile, for clinical symptoms, fluticasone/salmeterol was trade-off with budesonide/formoterol.
Downloads
References
Yawn BP, Mintz ML, Doherty DE. GOLD in practice: Chronic obstructive pulmonary disease treatment and management in the primary care setting. Int J Chron Obstruct Pulmon Dis. 2021;16:289–99.
Iglesias JR, Díez-Manglano J, García FL, Peromingo JAD, Almagro P, Aguilar JMV. Management of the COPD patient with comorbidities: An experts recommendation document. Int J Chron Obstruct Pulmon Dis. 2020;15:1015.
Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–82.
Jardim JR, Nascimento OA. The importance of inhaler adherence to prevent COPD exacerbations. Medical Sciences. 2019;7(4):54.
Shetty N, Cipolla D, Park H, Zhou QT. Physical stability of dry powder inhaler formulations. Expert Opin Drug Deliv. 2020;17(1):77–96.
Ozdemir T, Kilic H, Demirci NY, Ozdilekcan C, Bektemur G, Turkkani MH, et al. Five-year trends in direct costs of chronic obstructive pulmonary disease in turkey: COPDTURKEY-3. Turk Thorac J. 2021;22(5):393–8.
Alaydrus S. Analisis biaya pengobatan penyakit paru obstruktif kronik pasien rawat inap rumah sakit umum daerah kabupaten sukoharjo. Jurnal Ilmiah Farmasi Farmasyifa. 2020;3(1):51–61.
Voorham J, Corradi M, Papi A, Vogelmeier CF, Singh D, Fabbri LM, et al. Comparative effectiveness of triple therapy versus dual bronchodilation in COPD. ERJ Open Res. 2019;5(3):00106–2019.
Choi JY, Rhee CK. Diagnosis and treatment of early chronic obstructive lung disease (COPD). J Clin Med. 2020;9(11):1–20.
Gutiérrez Villegas C, Paz-Zulueta M, Herrero-Montes M, Parás-Bravo P, Madrazo Pérez M. Cost analysis of chronic obstructive pulmonary disease (COPD): A systematic review. Health Econ Rev. 2021;11(1):31.
Franklin M, Lomas J, Richardson G. Conducting value for money analyses for non-randomised interventional studies including service evaluations: An educational review with recommendations. Pharmacoeconomics. 2020;38(7):665–81.
Tonin FS, Aznar-Lou I, Pontinha VM, Pontarolo R, Fernandez-Llimos F. Principles of pharmacoeconomic analysis: The case of pharmacist-led interventions. Pharm Pract (Granada). 2021;19(1):1–10.
Qu S, You X, Liu T, Wang L, Yin Z, Liu Y, et al. Cost-effectiveness analysis of COPD screening programs in primary care for high-risk patients in china. NPJ Prim Care Respir Med. 2021;31(1):28.
Patel AR, Patel AR, Singh S, Singh S, Khawaja I. Global initiative for chronic obstructive lung disease: The changes made. Cureus. 2019;11(6):e4985.
Fazleen A, Wilkinson T. Early COPD: Current evidence for diagnosis and management. Ther Adv Respir Dis. 2020;14:1753466620942128.
Stridsman C, Svensson M, Johansson Strandkvist V, Hedman L, Backman H, Lindberg A. The COPD assessment test (CAT) can screen for fatigue among patients with COPD. Ther Adv Respir Dis. 2018;12:1753466618787380.
Sim YS, Lee JH, Lee WY, Suh DI, Oh YM, Yoon JS, et al. Spirometry and bronchodilator test. Tuberc Respir Dis (Seoul). 2017;80(2):105–12.
Gold WM, Koth LL. Pulmonary function testing. In: Murray and Nadel’s Textbook of Respiratory Medicine. Elsevier; 2016. p. 407–35.
Hoesterey D, Das N, Janssens W, Buhr RG, Martinez FJ, Cooper CB, et al. Spirometric indices of early airflow impairment in individuals at risk of developing COPD: Spirometry beyond FEV1/FVC. Respir Med. 2019;156:58–68.
Lorensia A, Pratama AM, Hersandio R. Knowledge and attitudes on smoking cessation of e-cigarettes: A mixed-methods study of pharmacy students in surabaya, indonesia. J Prev Med Hyg. 2022;62(4):E918–25.
Zhang H, Wu F, Yi H, Xu D, Jiang N, Li Y, et al. Gender differences in chronic obstructive pulmonary disease symptom clusters. Int J Chron Obstruct Pulmon Dis. 2021;16:1101–7.
Divo MJ, Celli BR, Poblador-Plou B, Calderón-Larrañaga A, de-Torres JP, Gimeno-Feliu LA, et al. Chronic obstructive pulmonary disease (COPD) as a disease of early aging: Evidence from the EpiChron Cohort. PLoS One. 2018;13(2):e0193143.
Moryson W, Stawinska-Witoszynska B. Premature mortality due to chronic obstructive pulmonary disease (COPD) in Poland. Medicina (B Aires). 2021;57(2):1–7.
Gülşen A. Pulmonary function changes in chronic obstructive pulmonary disease patients according to smoking status. Turk Thorac J. 2020;21(2):80–6.
Janson C. Treatment with inhaled corticosteroids in chronic obstructive pulmonary disease. J Thorac Dis. 2020;12(4):1561–9.
Lorensia A, Muntu CM, Suryadinata RV, Septiani R. Effect of lung function disorders and physical activity on smoking and non-smoking students. J Prev Med Hyg. 2021;62(1):E89–96.
Miravitlles M, Ribera A. Understanding the impact of symptoms on the burden of COPD. Respir Res. 2017;18(1):1–11.
Tamminen K, Laine J, Soini E, Martikainen J, Kankaanranta H. Cost-effectiveness analysis of budesonide/formoterol maintenance and reliever therapy versus fixed combination treatments for asthma in Finland*. Curr Med Res Opin. 2008;24(12):3453–61.
Roberts M, Mapel D, Petersen H, Blanchette C, Ramachandran S. Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management. J Med Econ. 2011;14(6):769–76.
Downloads
Additional Files
Published
Issue
Section
License
- The authors own the copyright of published articles. Nevertheless, Jurnal Respirologi Indonesia has the first-to-publish license for the publication material.
- Jurnal Respirologi Indonesia has the right to archive, change the format and republish published articles by presenting the authors’ names.
- Articles are published electronically for open access and online for educational, research, and archiving purposes. Jurnal Respirologi Indonesia is not responsible for any copyright issues that might emerge from using any article except for the previous three purposes.
